GSK lifted profit guidance for the year on Wednesday after sales of the drugmaker's 'specialty' medicines soared.

(Alliance News) - GSK predicted an annual outturn at the top end of guidance, BAE Systems maintained its outlook, while Aston Martin softened its profit forecast. Here is what you need to know before ...

Wall Street shares last night weakened, with the S&P 500 index down 0.3% ahead of tonight’s interest rate decision and latest batch of megacap earnings. The Dow Jones Industrial Average also fell 0.5% ...

Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 7.8% in the morning session after the ...

The FTSE 100 enjoyed another leap towards record territory as the index pushed around 0.7 per cent higher on Tuesday, ...

Tempus AI's growth is fueled by data services and acquisitions, despite financial risks. Key Q2 results may shape its path to ...

Against steep odds and well-established paradigms, these four companies have successfully been commercializing their products ...

Actuate Therapeutics' elraglusib shows promise in metastatic pancreatic cancer. Upcoming FDA meeting may accelerate approval.

The FTSE 100 has ticked up this morning after what became a wobbly session on Monday, with a stack of fresh earnings updates helping traders early on Tuesday. Entain and Games Workshop are leading ...

We expect Moderna MRNA to surpass expectations when it reports second-quarter 2025 earnings on Aug. 1, before the opening ...

British drugmaker GSK expects annual sales and profit to be towards the top of its forecast range, after second-quarter sales ...

British pharmaceutical company GlaxoSmithKline on Wednesday said its annual performance should be better than expected, despite US tariffs, after sales of its cancer drugs jumped in the second quarter ...